Discovery To Hope: Advancing Vector-Based Gene Therapies For Parkinson’s Disease

Experts in vector-based gene therapy share insights into developing a treatment for Parkinson’s disease and a view into the future of this new medical frontier.

Vector-based gene therapies represent a frontier in medical science, offering new hope for treating a wide range of complex genetic disorders. In this webinar, Dr. Jennifer Johnston, Ph.D., co-founder and CEO of NysnoBio, will describe her team's groundbreaking journey in developing an adeno-associated virus (AAV)-based gene therapy for Parkin-PD, a genetic form of Parkinson's disease that can affect individuals as young as 21 years old. 

Gain an inside look at:

• The science and technology behind the development and testing of viral vectors
• The advantages and efficacy of the baculovirus expression vector system (BEVS) in gene therapy
• Transitioning from small-scale proof of concept to larger-scale GMP viral vector manufacturing
• How partnering with large and experienced CDMOs can help advance treatment development

Complete the form to register

Meet the Speakers

Jennifer A. Johnston, PhD

Cofounder and CEO,
NYSNObio, LLC

Read bio →

Pouria Motevalian, PhD

Director, Bioprocess Sciences
Viral Vector Services
Thermo Fisher Scientific

Read bio →